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In patients with colorectal carcinoma, high levels of circulating
carcinoembryonic antigen (CEA) are associated with poor prog-
nosis. After surgical removal of a primary tumour, increasing
circulating CEA levels often precede the development of meta-
stases, especially liver metastases (Lucha et al, 1997). Thus, there
is a clear relationship between circulating CEA levels and metas-
tases, but it is impossible to demonstrate in humans a connection
between cause and effect.
Several authors have demonstrated that CEA can be considered
as an adhesion molecule (Benchimol et al, 1989; Oikawa et al,
1989; Pignatelli et al, 1990). The question addressed in the present
study was to determine whether these adhesive properties facilitate
the development of liver metastases from colorectal cancer. Up to
now, the involvement of CEA in the development of liver metas-
tases from colorectal cancers has been addressed in two different
ways: (i) comparison of the metastatic potential of different human
colon carcinoma cell lines or CEA-transfected cells in association
with CEA membrane expression (Tibbetts et al, 1993; Thomas et
al, 1995; Landuzzi et al, 1996); (ii) analysis of the effect of circu-
lating CEA on the development of liver metastases from different
human colon carcinoma cells (Hostetter et al, 1990; Jessup et al,
1993a). This second approach is particularly interesting since one
can imagine different strategies for modifying circulating CEA
levels such as its capture with anti-CEA monoclonal antibodies
(mAb). If there is a cause–effect relationship between circulating
CEA levels and the development of liver metastases from
colorectal cancer, the elimination of CEA from the blood stream
in patients would be expected to reduce the possibility of their
developing such metastases.
To test this hypothesis, instead of injecting CEA into the blood-
stream of tumour-bearing nude mice, we propose a new animal
model in which a CEA-secreting subcutaneous (s.c.) tumour gives
rise to different circulating CEA levels as a function of the tumour
volume. Using this model, we induced liver metastases from three
different colon carcinoma cell lines expressing high levels of
membrane CEA (LS174T, LoVo and CO112). We demonstrated
that the number and size of the liver metastases depended on the
cell line and the eventual resection of the s.c. tumour but were not
related to the circulating CEA levels.
MATERIALS AND METHODS
Cell lines
The LS174T (ATCC CL188) and the LoVo (ATCC CCL229) cell
lines were purchased from the American Type Culture Collection.
The CO112 cell line was established by Mach et al (1974). These
three human colon carcinoma cell lines were used as positive
controls in the screening and characterization of the transfectants and
for metastatic potential assay. The CEA-negative subclone from
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Summary Both experimental and clinical data show evidence of a correlation between elevated blood levels of carcinoembryonic antigen (CEA)
and the development of liver metastases from colorectal carcinomas. However, a cause–effect relationship between these two observations has
not been demonstrated. For this reason, we developed a new experimental model to evaluate the possible role of circulating CEA in the
facilitation of liver metastases. A CEA-negative subclone from the human colon carcinoma cell line CO115 was transfected either with CEA-
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leading to the synthesis of the entire CEA molecule linked to the cell surface by a GPI anchor. Transfectants were selected either for their high
CEA secretion (clone CO115-2C2 secreting up to 13 mg CEA per 106 cells within 72 h) or for their high CEA membrane expression (clone CO115-
5F12 expressing up to 1 ´ 106 CEA molecules per cell). When grafted subcutaneously, CO115-2C2 cells gave rise to circulating CEA levels that
were directly related to the tumour volume (from 100 to 1000 ng ml–1 for tumours ranging from 100 to 1000 mm3), whereas no circulating CEA
was detectable in CO115 and CO115-5F12 tumour-bearing mice. Three series of nude mice bearing a subcutaneous xenograft from either clone
CO115-2C2 or the CO115-5F12 transfectant, or an untransfected CO115 xenograft, were further challenged for induction of experimental liver
metastases by intrasplenic injection of three different CEA-expressing human colorectal carcinoma cell lines (LoVo, LS174T or CO112). The
number and size of the liver metastases were shown to be independent of the circulating CEA levels induced by the subcutaneous CEA
secreting clone (CO115-2C2), but they were directly related to the metastatic properties of the intrasplenically injected tumour cells.
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Correspondence to: A Pèlegrinhuman colon carcinoma cell line CO115 was established in one of
our laboratories (Mach et al, 1974; Carrel et al, 1976). The cells were
transfected with truncated CEA-cDNA as described in a previous
study where the isolation of the CO115–2C2 clone is reported. In
culture, CO115–2C2 secretes up to 13 mg fully immunoreactive CEA
per 106 cells within 72 h (Terskikh et al, 1993).
Full-length CEA-cDNA transfection
CO115 cells were transfected with pRc/CMV/CEA-cDNA
(Pèlegrin et al, 1992) using a mammalian transfection kit
(Stratagene, La Jolla, CA, USA). Three mg of DNA were precipi-
tated with calcium phosphate according to the manufacturer’s
instructions and incubated for 16 h with about 3 ´ 106 non-
confluent adherent carcinoma cells. Fresh culture medium was
then added. After a further 24-h incubation, the cells were
harvested and divided in two 75 cm2 culture flasks and grown for
24 h before adding the Neomycin analogue G418 (Gibco, Paisley,
UK) at a concentration of 200 mg ml–1. This concentration of G418
was shown to be three times the minimal lethal dose for non-trans-
fected CO115 cells. Cells resistant to G418 were expanded and
tested for CEA expression by flow cytometry using a fluores-
cence-activated cell sorter (FACS) (Becton-Dickinson, Mountain
View, CA, USA). CEA-positive cells were sorted and cloned by
limiting dilution.
FACS analysis
Cells were incubated for 15 min at 37°C with trypsin (2.5 mg
ml–1), washed once in RPMI medium 10% fetal calf serum (FCS)
and then washed twice in phosphate-buffered saline (PBS)
containing 1 mg ml –1 bovine serum albumin (BSA). This buffer
was used for all the washing steps, except for the last one in which
BSA was omitted. For CEA-cDNA transfectant screening, about
5 ´ 105 cells were incubated for 1 h with a pool of four anti-CEA
mAb (35A7, CE25, B93, B17) labelled with fluoroscein isothio-
cyanate (FITC Isomer I, Sigma, St Louis, MO, USA) and then
washed twice before FACS analysis. For CEA epitopes analysis,
five mAb directed against the five CEA epitopes were used as
primary antibody followed by a fluorosceine-labelled sheep
anti-mouse F(ab´)2 as secondary antibody (Silenus, Victoria,
Australia). Fluoroscein-labelled or unlabelled normal mouse IgG1
was used for background measurement. The samples were
analysed on a FACScanII (Becton-Dickinson). Each figure repre-
sents data obtained from the analysis of 10 000 cells.
The GPI anchorage of CEA was analysed by phosphatidyl-
inositol-specific phospholipase C (PI-PLC) treatment of the cells
before FACS analysis. Five to 10 ´ 106 tumour cells were treated
with 0.5–1.0 unit PI-PLC (Boehringer Mannheim, Germany) for
1 h at 37°C in PBS containing 1 mg ml–1 BSA.
Immunocytochemical analysis
Cells were centrifuged on SuperFrost Plus microscope slides and
fixed in methanol:acetone (1:1) for 10 min at –20°C. Endogenous
peroxidase activity was inhibited by incubating sections in 0.3%
hydrogen peroxide for 5 min. The anti-CEA chimeric mouse-
human mAb X4 (Hardman et al, 1989) was used as primary anti-
body (10 mg ml–1 for 30 min) followed by incubation for 30 min
with horseradish peroxidase-conjugated anti-human IgG (Dako,
P214; diluted 1:50). The staining reaction was performed using
AEC as substrate. Slides were counterstained with haematoxylin.
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Table 1 Experimental liver metastasis after intrasplenic injection of LoVo, LS174T or CO112 cells in nude mice bearing CO115, CO115-5F12 or CO115-2C2
tumours
Liver metastasis gradea Circulating CEA (ng/ml)
Subcutaneous Mice
Intrasplenic Subcutaneous tumour (evaluable/
0 I II III IV D-1b D+7 D+15
injection tumour resection Sacrifice included)
LoVo CO115–2C2 – D+29 12/13 9 3 46–400 (173)c ––
– – D+29 11/11 9 2 < 5 – –
LoVo CO115–5F12 D+7 D+42 8/8 5 1 2 < 5 < 5 < 5
CO115–2C2 D+7 D+42 12/12 7 3 2 24–818 (238) 252–1970 (842) < 5
LoVo CO115 D+7 D+42 6/6 4 2 < 5 < 5 < 5
CO115–5F12 D+7 D+42 6/6 5 1 < 5 < 5 < 5
CO115–2C2 D+7 D+42 7/8 4 1 2 23–192 (119) 157–600 (364) < 5
LS174T CO115 – D+11 6/6 3 3 < 5 – –
CO115–5F12 – D+11 6/6 2 4 < 5 – –
CO115–2C2 – D+11 6/6 1 3 2 22–266 (128) – –
– – D+11 2/2 2 < 5 – –
LS174T CO115 D+7 D+27 3/6 1 1 1 < 5 < 5 < 5
CO115–5F12 D+7 D+27 5/6 1 1 1 2 < 5 < 5 < 5
CO115–2C2 D+7 D+27 7/8 1 2 2 2 150–533 (298) 147–957 (524) < 5
CO112 CO115 D+7 D+27 5/6 1 1 1 2 < 5 < 5 < 5
CO115–5F12 D+7 D+27 6/6 2 1 3 < 5 < 5 < 5
CO115–2C2 D+7 D+27 6/8 1 1 2 2 113–500 (404) 141–977 (439) < 5
aTumour burden was assessed according to the classification of Giavazzi et al (1986): 0, no tumour deposit, tumour-free; I, histological evidence of tumour
growth or one isolated metastasis; II, fever than ten tumour foci, < 1–2 mm in diameter; III, 10–100 tumour foci, 3–5 mm in diameter; IV, more than 100 tumour
foci, > 5 mm in diameter. Each value represents the number of mice for each metastatic grade. bAll the dates are expressed in days (D), D0 being the day of
intrasplenic injection of LoVo, LS174T or CO112 cells. cRange. Average value is indicated in parenthesis.CEA measurements
The concentration of CEA in the culture supernatant and in the
serum of nude mice bearing different subcutaneous (s.c.) tumours
was determined using a radioimmunoassay (ELSA2-CEA in vitro
test®, CIS Bio International, Gif-Sur-Yvette, France).
Animal subcutaneous tumour inoculation and tumour
resection
Experiments were performed on 6- to 8-week-old female BALB/c
nude mice (Iffa-Credo, L’Arbresle, France). Mice had free access
to feed and water and were housed five mice per cage under
specific pathogen-free conditions. All experimental protocols were
performed in accordance with the French guidelines for experi-
mental animal studies. CO115 and derived tumours were propa-
gated by serial s.c. transplantation into the right flanks of the mice.
Tumour size was evaluated by measuring the tumour diameters
(three dimensions) and the volume was calculated by the formula:
vol = r1 ´ r2 ´ r3 ´ 4p/3 where r is the radius.
For s.c. tumour resection, the mice were anaesthetized with
2,2,2 tribromoethanol 0.5 mM in 10% ethanol and 90% sodium
chloride (10 ml kg–1). During tumour resection, special care was
taken to avoid the release of tumour cells into the tumour venous
effluent by clamping blood vessels.
Metastatic potential assay
The potential of cell lines to form experimental metastases was
examined in BALB/c nude mice after intrasplenic (i.s.) injection
according to Kozlowski et al (1984). Special care was taken to
obtain single cell preparations to eliminate the possibility of liver
metastases due to vascular embolism. Cells were incubated for
15 min at 37°C with trypsin (2.5 mg ml–1) and then washed once
with RPMI-1640 10% FCS and twice with PBS without Ca++ or
Mg++. Cells were kept for 30 min at 4°C in PBS before the last
washing. Mice were anaesthetized and, after a laparotomy, given
an i.s. injection of 5 ´ 105 cells in 50 ml through a 26-gauge needle.
All groups were sacrificed when mice in any group became mori-
bond. Autopsies were performed and the presence of metastases
was determined by macroscopic inspection and confirmed histo-
logically. Tumour burden was assessed according to the classifica-
tion of Giavazzi et al (1986): 0, no tumour deposit, i.e.
tumour-free; I, histological evidence of tumour growth or one
isolated metastasis; II, fewer than ten tumour foci, < 1–2 mm in
diameter; III, 10–100 tumour foci, 3–5 mm in diameter; IV, more
than 100 tumour foci, > 5 mm in diameter.
Statistical analysis
The Kruskal–Wallis test or the c2 distribution was performed to
analyse the statistical significance of the effect of the circulating
CEA and liver metastases 1375
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Figure 1 (A) Flow cytometry analysis of full-length and truncated CEA-cDNA transfected clones and the parental cell line CO115. mAb 35A7 specific for the
CEA Gold 2 epitope (grey shading) and an irrelevant IgG (no shading) were used as primary antibody. CO115: parental CEA-negative human colon carcinoma
cell line; CO115-5F12: CO115 transfected with full-length CEA-cDNA; CO115–2C2: CO115 transfected with truncated CEA-cDNA. (B) Flow cytometry analysis
of CEA expression by the three colon carcinoma cell lines used for the metastatic potential assay: LS174T, LoVo and CO112. The same specific mAb for the
CEA Gold 2 epitope (grey shading) and an irrelevant IgG (no shading) were used. CEA expression was checked by FACS before any in vivo experiment using
these cell linesCEA levels, the type of cells injected and the s.c. tumour resection
status on the metastatic potential assay.
RESULTS
Transfection of full-length CEA-cDNA
The full-length CEA-cDNA construct was transfected into a CEA-
negative subclone from the human colon carcinoma cell line
CO115 by the calcium phosphate precipitation method. The trans-
fected cells were selected first with the neomycin analogue G418.
In the G418-resistant cells, 10% were found to be CEA-positive by
flow cytometry using a pool of CEA-specific mAb labelled with
fluoroscein. The cells were sorted and cloned by limiting dilution.
Out of 960 initials wells, 100 clones were isolated. Eight of them
were further characterized, but only one (CO115-5F12) was used
for the following experiments.
Expression of CEA in CO115 cells transfected with full-
length or truncated CEA-cDNA
FACS analysis showed that the parental cell line CO115 expressed
none of the four CEA-specific epitopes (Gold 1–4) but only the
Gold 5 epitope which is shared with the non-specific cross-
reacting antigen NCA (Hammarstrom et al, 1989). After transfec-
tion with the full-length CEA-cDNA, the clones were found to
express all the CEA epitopes Gold 1–5. The CEA molecule
expressed by the transfected clones was PI-PLC sensitive
confirming a GPI anchor of the molecule. We selected clone
CO115-5F12 for the following study because it was one of the
higher CEA expressers (Figure 1A). After transfection with trun-
cated CEA-cDNA, no membrane expression was detectable in any
of the transfected clones (Figure 1A). This was illustrated with
clone CO115-2C2 which was selected for the present study
because it has been shown to secrete up to 13 mg CEA per 106 cells
within 72 h in the culture supernatant (Terskikh et al, 1993).
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Figure 2 Immunocytochemical analysis of CEA expression of full-length and truncated CEA-cDNA-transfected clones and parental cell line CO115. The
parental cell line, CO115, did not express CEA (A). The full-length CEA-cDNA-transfected clone, CO115-5F12, expressed CEA mainly at the membrane level
(C); whereas in the truncated CEA-cDNA transfected clone, CO115-2C2, the CEA expression was limited to the cytoplasm (E). An irrelevant IgG was used as
negative control with the three cell lines (B, CO115; D, CO115–5F12; F, CO115-2C2)CEA expression following the two different transfections was
also analysed by immunocytochemistry (Figure 2). Binding of the
anti-CEA antibodies revealed a clear membrane expression of the
antigen in clone CO115-5F12, whereas only cytoplasmic expres-
sion was found in clone CO115-2C2. This observation confirmed
the results of our previous study where we demonstrated that dele-
tion of the 78 bp at the 3¢ end of the CEA-cDNA, encoding the 26-
amino acid hydrophobic domain, induced active secretion of CEA
(Terskikh et al, 1993).
Development of an animal model with different levels of
circulating CEA: CO115-2C2 tumour-bearing nude mice
The parental CO115 cells and the transfected clones, CO115-5F12
and CO115-2C2, were grafted s.c. into the right flanks of BALB/c
nude mice and the resulting tumours were propagated by serial s.c.
transplantation. Serum-circulating CEA was measured at different
times and expressed as a function of the tumour volume. Mice
bearing the CO115-2C2 tumours showed a clear correlation
between these two parameters (Figure 3). The regression equation
was given by log10 (serum CEA) = 0.574 + 0.814 log10 (tumour
volume). The linear correlation coefficient of this equation is r =
0.704. For tumours ranging from 100 to 1000 mm3, we observed
serum CEA values ranging from 100 to 1000 ng ml–1. No CEA was
detectable in the serum of mice bearing the CO115 or the CO115-
5F12 tumours.
Metastatic potential assay
Three human colon carcinoma cell lines were selected for the
metastatic potential assay: LS174T (ATCC CL188), LoVo (ATCC
CCL229) and CO112 (Mach et al, 1974) according to their high
CEA expression which was confirmed by FACS analysis before
any in vivo experimentation (Figure 1B).
For the metastatic potential assay, mice were first s.c. grafted
with the CO115, CO115-5F12 or CO115-2C2 tumour. When the
tumours had reached a volume of about 100–200 mm3, blood
samples were taken and CEA was measured in the serum.
Depending on the tumour volume, mice bearing CO115-2C2
tumours showed circulating CEA levels ranging from 22 to 818 ng
ml–1 (Table 1). Intrasplenic injections of LS174T, LoVo or CO112
cells were performed the next day. Special care was taken to inject
single cells because cell aggregates could be arrested in capillary
beds enhancing the experimental metastatic potential of the cells
(Liotta et al, 1976).
With the LoVo and LS174T cell lines, two different protocols
were performed. In the first procedure, the s.c. tumours were kept
on the mice after the i.s. injection of the LS174T or the LoVo cells.
Because of the cumulated morbidity due to the presence of both the
s.c. and the i.s. tumours, this procedure led to the necessity to sacri-
fice the mice at a relatively short time after the i.s. injection, that is
day 11 and 29 post i.s. injection for the LS174T and LoVo cells
respectively. To avoid this problem, a second protocol was designed
in which the s.c. tumours were resected on day 7 after the i.s. injec-
tion of LS174T or LoVo cells. This allowed us to keep the mice
alive for up to 27 and 42 days post i.s. injection of the LS174T and
LoVo cells respectively. Only the second protocol was used for the
CO112 cell line. A kinetic analysis of circulating CEA showed a
clear increase for the 7 days between the i.s. injection of cells (D0)
and s.c. tumour resection (D7) (Table 1). The CEA depletion
occurred in about 2 days giving, for example, values of 86.5, 41.5
and 39.5 ng ml–1 24 h after s.c. tumour resection in mice with 960,
327 and 283 ng CEA per ml, respectively, the day before resection.
The experimental liver metastases data are presented in Table 1.
Whatever the s.c. tumour and the resection status, i.s. injection of
LoVo cells induced metastases which did not exceed grade II.
Grades III and IV were observed more frequently with LS174T
cells and, in particular, with CO112 cells. This difference between
the ability of the three cell lines to induce liver metastases was
shown to be statistically significant (P = 0.0001 by the
Kruskal–Wallis test). The s.c. tumour resection affected liver
metastases development essentially for LS174T cells for which
CEA and liver metastases 1377
British Journal of Cancer (1999) 80(9), 1373–1379 © 1999 Cancer Research Campaign 
10 000
1
10
100
1000
S
e
r
u
m
 
C
E
A
 
(
n
g
 
m
l
–
1
)
1 10 100 1000 10 000
Tumour volume (mm3)
Figure 3 Serum CEA concentration expressed as a function of tumour
volume in CO115-2C2 tumour-bearing mice. The regression equation was
given by log10 (serum CEA) = 0.574 + 0.814 log10 (tumour volume). The linear
correlation coefficient of this equation is r = 0.704. No circulating CEA was
detectable in mice bearing the CO115 or the CO115-5F12 tumours
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Figure 4 Summary of the metastatic potential assay. The mice described in
Table 1 were divided into two groups: mice with no circulating CEA (i.e.
bearing s.c. the CO115 or CO115-5F12 tumour, or no s.c. tumour) and mice
with circulating CEA (i.e. bearing the s.c. CO115-2C2 tumour). The results
are expressed as a percentage of mice without n n or with liver metastasis n
whatever the grade following i.s. injection of the different cell lines, i.e. LoVo,
LS174T or CO112. The exact number of mice in each group is indicatedgrade III and IV were more frequent after resection as compared
with mainly grade II without resection. A global analysis of the
resection status of the LS174T and LoVo cells showed a difference
close to statistical signification (P = 0.0512). Whatever the protocol
used (cell line, resection status), circulating CEA levels did not
affect the liver metastases development (P = 0.734). In all cases, the
CO115-2C2 tumour-bearing mice developed liver metastases close
to those observed in non-CEA secreting tumour-bearing mice. All
these data are summarized in Figure 4 where the results are
expressed in percentage of mice with or without liver metastases as
a function of the presence or absence of circulating CEA and the
type of i.s. injected cell line. In this summarized form, there appears
to be more metastases in the mice with circulating CEA but the
difference remains non-significant: P = 0.29 and P = 0.36 for the
LoVo and LS174T cell lines respectively (c2 distribution).
DISCUSSION
Circulating CEA is related to poor prognosis in colorectal cancer
patients. Because the precise involvement of this tumour marker in
the development of liver metastases cannot be analysed in humans,
many studies have been conducted using animal models to try to
demonstrate a connection between cause and effect. Most of the
studies designed to address this question were based on the
hypothesis that the adhesive properties of CEA might facilitate the
development of liver metastases from colorectal cancer (Hostetter
et al, 1990; Jessup et al, 1993a; Tibbetts et al, 1993; Thomas et al,
1995; Landuzzi et al, 1996). Recently, some authors suggested that
CEA could enhance liver metastases via induction of cytokines in
Kupffer cells (Gangopadhyay et al, 1996; Edmiston et al, 1997).
The adhesive properties of CEA have been demonstrated in vitro
with different colon carcinoma cell lines expressing CEA and NCA
or CHO cells transfected with CEA or NCA cDNA. Such cells are
able to form homotypic aggregates (CEA–CEA or NCA–NCA) and
to a lower extent heterotypic ones (CEA–NCA) (Benchimol et al,
1989; Oikawa et al, 1989; Zhou et al, 1990). Two different CEA
epitopes are presumed to be necessary for CEA–CEA interactions
(Jessup et al, 1993b). Zhou et al (1993) proposed an interaction
model involving the N-terminal and A3 domains. Contribution of the
N-terminal domain was confirmed by different authors but that of the
A3 domain was contested (Jessup et al, 1993b; Hashino et al, 1994).
Whatever the domains involved, CEA could promote the develop-
ment of liver metastases through homotypic or heterotypic adhesion
between carcinomas cells themselves or between carcinoma cells
and CEA trapped at the surface of Kupffer cells (Toth et al, 1992;
Jessup et al, 1993a). Using ten human colon carcinoma cell lines,
Tibbetts et al (1993) demonstrated that there is a connection
between membrane CEA expression and the development of exper-
imental liver metastases following i.s. injection of the cells. The high
CEA-expressing cell lines gave metastases more frequently than the
low-expressing ones, but there was not an absolute correlation.
Hashino et al (1994) used CHO cells transfected with the CEA-
cDNA and obtained 100% metastases with the CHO cells
expressing CEA as compared with no metastasis with the CHO
mock-transfected cells. In all these studies, the development of liver
metastases was correlated with the early retention of the cells in the
liver and the in vitro adhesion properties of the cells (Jessup et al,
1993a). The relationship between adhesion properties and the devel-
opment of liver metastases was confirmed in a study by Landuzzi et
al (1996) who reported an inhibition of lung metastases after trans-
fection of the CEA-cDNA in the human rhabdomyosarcoma cell
line RD/18. The decrease of lung metastases was clearly related to a
decrease of adhesion properties of the cells after transfection. In a
homotypic adhesion test, the transfected cells gave more than 60%
single cells as compared with about 20% for the parental cell line.
On the basis of these studies on membrane CEA and liver metas-
tases, it appears that CEA is certainly one of the molecules involved
in cell–cell interaction, but many other molecules probably also
participate in this phenomenon. The nature and the number of these
molecules can vary from one type of cell to another, accounting for
conflicting results reported by different authors (Jessup et al, 1993a;
Landuzzi et al, 1996). In all the cases, the single cell nature of the
cell preparation used for the induction of experimental liver metas-
tases is a primordial parameter. Cell aggregates can arrest in capil-
lary beds enhancing the experimental metastatic potential of cells
(Liotta et al, 1976).
To analyse the involvement of circulating CEA on the develop-
ment of liver metastases from colorectal carcinoma in nude mice,
Jessup et al (1993a) and Hostetter et al (1990) injected CEA i.v.
30 min before i.s. injection of different human colon carcinoma
cell lines. A 40-mg CEA dose enhanced experimental liver metas-
tases following injection of three poorly metastatic cell lines (KM-
12c, MIP-101 and Clone A) or highly metastatic ones (CCL 235,
HT 29 and mHC 1410). The authors observed a significant corre-
lation between the formation of experimental metastases and the
early retention of tumour cells in the liver. From our point of view,
the limitation of these studies was the use of an i.v. bolus injection
of CEA to obtain circulating CEA in the nude mouse model. The
40-mg dose of injected CEA gave about 400 ng CEA per ml serum
4 h post-injection, but only 12 ng CEA per ml serum 20 h later.
Although according to the authors, this experimental procedure
gave about 75 ng CEA per mg liver protein 4 h after CEA injec-
tion, this appears to us to be a situation quite different from that
observed in patients with increasing circulating CEA levels. In
such cases, the CEA from the tumour is shed into the circulation
and cleared by the liver where it binds first to Kupffer cells in
which the terminal sialic acid residues are removed. Asialo-CEA
is then transferred to hepatocytes where it is degraded (Hostetter et
al, 1990; Gangopadhyay et al, 1996). An increase in circulating
CEA levels thus corresponds to the saturation of the liver sites by
the CEA shed from the tumour.
For this reason, we developed a new animal model mimicking the
human situation of increasing circulating CEA levels. Because
human colon carcinoma s.c. grafted into nude mice give no
detectable circulating CEA (Folli et al, 1993), we used a CEA-nega-
tive clone of the colon carcinoma cell line CO115 transfected with
truncated CEA-cDNA lacking the 78 base pairs at the 3¢ region
encoding the 26-amino acid hydrophobic domain. This transfected
cell line, CO115-2C2, was shown to actively secrete CEA into the
culture (Terskikh et al, 1993). When grafted s.c. into nude mice,
CO115-2C2 cells gave CEA-secreting tumours producing circu-
lating CEA levels ranging from 100 to 1000 ng ml–1 with s.c.
tumours as small as 100–1000 mm3. We observed a clear correlation
between circulating CEA levels and tumour volume (Figure 3).
We used this animal model to analyse the involvement of
circulating CEA in the development of liver metastases induced
experimentally by i.s. injection of human colon carcinoma cells
(Kozlowski et al, 1984). We focused our attention on three cell
lines (LS174T, LoVo and CO112) which express high amounts of
membrane CEA as determined by FACS analysis. Depending on
the i.s. injected cell line and the protocol used (involving or not s.c.
tumour resection), we obtained all the possible grades of liver
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the animals alive longer: 42 and 27 days as compared with 29 and
11 days without resection for LoVo and LS174T respectively.
Circulating CEA did not significantly affect the number or the size
of the liver metastases with either of the cell lines used or protocols
tested (Table 1 and Figure 4).
Our experimental model, which closely resembles the clinical
situation, did not allow us to demonstrate any effect of circulating
CEA on the development of liver metastases. This animal model in
which there is a direct relationship between the volume of the
tumour and the level of circulating CEA could be used to study, for
example, the influence of circulating CEA on tumour targeting
with anti-CEA mAbs (Buchegger et al, 1995).
The purpose of the present study was not to analyse the effect of
membrane CEA on the development of liver metastases from
colorectal cancer since this parameter is specific for each tumour
and cannot be modified by any treatment. Our purpose was to eval-
uate the eventual effect of circulating CEA on the development of
liver metastases. The question was addressed by using three cell
lines expressing high levels of membrane CEA. On the basis of the
results obtained with these three cell lines, we conclude that circu-
lating CEA is not involved in the development of liver metastases
from colorectal cancers. Membrane CEA could enhance liver
metastases by the formation of cell aggregates trapped in the small
venules of the liver. In this case, CEA would be responsible for the
attachment of carcinoma cells in clusters, but the binding of these
clusters in the liver is only a mechanistic phenomenon and is not
due to homophilic interactions between circulating cancer cells
and CEA expressed by Kupffer cells.
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